{"slug":"semax-diabetic-neuropathy","verification":{"valid":true,"entries":2,"head":"d9e92ff697660b2af8e1ea536beea44b4e07b4f937fcaa012167120027fbcdf1"},"energy":{"passes":2,"tokens_in":27095,"tokens_out":2836,"tokens_total":29931,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"d9e92ff697660b2af8e1ea536beea44b4e07b4f937fcaa012167120027fbcdf1"},"provenance":[{"ts":"2026-06-30T00:12:55.220Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Semax for Diabetic Neuropathy\nSlug: semax-diabetic-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_cross\",\"condition\":\"Diabetic neuropathy\",\"condition_key\":\"diabetic-neuropathy\",\"primary_peptide\":\"semax\",\"peptides_in_scope\":[{\"id\":\"semax\",\"name\":\"Semax\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down if you have Diabetic neuropathy\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"semax\",\"name\":\"Semax\",\"section_title\":\"Why Semax might help you\",\"layer\":\"neural / cognitive\",\"steps\":[\"You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\",\"**What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\",\"**What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating symptoms.\",\"**Therefore for you:** If that layer is part of your problem, Semax is discussed because it targets repair (neural / cognitive) — not because it masks pain.\"],\"prose\":\"1. You are reading about **Diabetic neuropathy** — what breaks down matters before any compound name.\\n2. **What keeps failing:** BDNF decline, stimulant-induced neuro stress, cognitive fatigue after dopamine load.\\n3. **What Semax is studied to do:** Studied for BDNF and neural support — building connections, not sedating symptoms.\\n4. **Therefore for you:** If that l","response":"{\n  \"slug\": \"semax-diabetic-neuropathy\",\n  \"title\": \"Semax for Diabetic Neuropathy: Evidence-Graded Review\",\n  \"body\": \"## What's breaking down if you have Diabetic neuropathy\\n\\nDiabetic neuropathy involves progressive damage to peripheral nerves caused by chronic high blood sugar. Layers include oxidative stress on nerve fibers, impaired blood flow from vascular changes, chronic low-grade inflammation, and reduced support from neurotrophic factors such as BDNF. Over time, repair pathways lag behind ongoing breakdown, leading to symptoms like numbness, pain, or weakness. The condition persists when degeneration outpaces the body's natural regeneration capacity.\\n\\n## Why Semax might help you\\n\\n1. You are reading about Diabetic neuropathy — what breaks down matters before any compound name.\\n2. What keeps failing: BDNF decline, impaired neural repair signaling, and oxidative/inflammatory stress on nerves.\\n3. What Semax is studied to do: Studied for BDNF upregulation and neural support — promoting connections and neuroprotection rather than sedating symptoms.\\n4. Therefore for you: If neural repair and BDNF support are part of your problem profile, Semax is discussed because it targets repair pathways — not because it masks pain or reduces mechanical load.\\n\\n## How these fit together\\n\\nSingle-compound focus. Semax targets the neural / cognitive layer through studied effects on BDNF and gene expression related to neurotransmission and inflammation. No multi-peptide stack data applies here.\\n\\n## What the evidence actually shows\\n\\nHuman data specific to diabetic neuropathy remains limited. A 2013 review references evaluation of Semax 0.1% in patients with nonproliferative diabetic neuropathy, but detailed outcomes, sample sizes, and controls are not elaborated in available summaries (Kolomin et al., 2013, review). No large randomized controlled trials in Western databases address Semax for this condition.\\n\\nPreclinical studies show Semax influences BDNF expressio","tokens_in":27095,"tokens_out":2836,"cost":0,"prev":"genesis","hash":"32ddc4f2e2f8cc089a3acdce0ed023f9b7c7471f05117d70564589d4631b6546"},{"ts":"2026-07-17T02:41:53.019Z","model":"owner","action":"voxel_divide","prompt":"","input":"semax-diabetic-neuropathy","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"32ddc4f2e2f8cc089a3acdce0ed023f9b7c7471f05117d70564589d4631b6546","hash":"d9e92ff697660b2af8e1ea536beea44b4e07b4f937fcaa012167120027fbcdf1"}]}